NCT01563185已完成4 期
A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 12
- 试验地点
- 5
- 主要终点
- Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
研究概览
简要总结
The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks.
The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
详细描述
Approximately 30 JIA patients who meet all eligibility criteria and who are expected to require daily administration of an NSAID for up to 24 weeks will be enrolled. A subset of approximately 6 patients will participate in a single dose PK study at Day 0 with an abbreviated PK profile performed at Week 4 if possible. Multiple dose PK sampling will occur in all enrolled patients.
Study with completed results acquired from Horizon in 2024
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient and guardian are willing to consent to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily.
- •Patient is male or female, aged 10 years to 16 years, 11 months.
- •Patient is diagnosed with JIA for > 1 month including oligoarthritis, polyarthritis rheumatoid factor (RF) +, polyarthritis RF-, psoriatic arthritis, enthesitis-related arthritis, or undifferentiated and systemic arthritis without systemic features in the past 6 months.
- •Patient must have currently active articular disease as defined by > 1 active joint (i.e., presence of swelling, or if no swelling is present, limitation of motion [LOM] accompanied by pain, tenderness, or both).
- •Based upon investigator judgment, given current treatment patient is receiving and level of disease activity, it is determined appropriate for the patient to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily. The investigator will use his/her clinical judgment in determining the duration of treatment for the patient based on the standard of care up to 24 weeks of treatment.
- •Weight > 48 kg and body mass index (BMI) > 5th percentile using the Centers for Disease Control (CDC) BMI percentile calculator for child and teen at the screening visit.
- •Patient is able to swallow a DUEXIS tablet whole.
- •For the single dose pharmacokinetic (PK) subset, patients and guardians must be willing to participate in the serial blood sample collections at Day 0 and Week
- •Female patients of childbearing potential and male patients must agree to use medically acceptable methods of contraception, including abstinence, throughout the entire study period.
- •Patient is willing and able to comply with the prescribed treatment protocol and evaluations.
排除标准
- •Patient has a history of or experienced any of the following:
- •NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding
- •NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis
- •Malignant disease of the gastrointestinal tract
- •Erosive esophagitis
- •Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0
- •Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c > 7%
- •Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C.
- •Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease.
- •JIA disease is severe as defined by either physician's or parent's global assessments > 90 on a 100 point scale.
- •Systemic JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
- •Active uveitis.
- •Presence of any other rheumatic disease or major chronic infectious, inflammatory, immunologic disease (e.g., inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus, etc.).
- •Presence at screening or history of any disease other than JIA that requires the use of chronic systemic corticosteroids.
- •History of clinically significant drug or alcohol abuse.
- •Presence at screening of any of the following laboratory values:
- •Hemoglobin < 9.0 g/dL
- •White blood cells < 2000/mm^3 (2 x 109/L)
- •Platelets < 150,000/mm^3 (150 x 109/L)
- •Serum creatinine > 1.5 times upper limit of normal
- •Serum ALT or AST > 2.0 times upper limit of normal
- •H. pylori positive
- •Any other lab value that in the opinion of the investigator might place the patient at unacceptable risk for participation in this study.
- •Methotrexate > 20 mg/M^2/week or > 40 mg/week.
- •Patient currently is participating in an investigational drug study, or patient participated in an investigational drug study within the 30 days (or < 5 terminal half-lives of elimination) prior to study entry.
- •Females who are pregnant or breast feeding.
- •Female patient has a positive serum pregnancy test at Screening and/or a positive urine pregnancy test at Study Day
- •Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk
研究组 & 干预措施
DUEXIS
Experimental
800 mg ibuprofen/26.6 mg famotidine
干预措施: 800 mg ibuprofen/26.6 mg famotidine (Drug)
结局指标
主要结局
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
时间窗: Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)
Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients.
次要结局
- Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)(Pre-dose, 0.5, 1, 2, 4, 8 hours post-dose)
- Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores(Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).)
- Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)(Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose)
- American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being(Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).)
- American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index(Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).)
- ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis(Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).)
- American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration(Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).)
- Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))(Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose)
- Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)(Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group)
- Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)(Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
4 期
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry DiseaseFabry DiseaseNCT00140621Genzyme, a Sanofi Company6
已完成
1 期
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionSevere Hemophilia ANCT04864743Jiangsu Gensciences lnc.13
已完成
3 期
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral BranchesCardiovascular AbnormalitiesNCT00310609Bayer123
已完成
3 期
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal ArteriesStenosisNCT00309075Bayer126
已完成
3 期
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal ArteriesRenal Artery StenosisNCT00310557Bayer116